Revista Científica de la Sociedad Española de Medicina de Urgencias y Emergencias
Subscríbete a nuestra newsletter
Factor de impacto 2022
5.5
1er cuartil (4 de 32)
Emergency Medicine
Resumen
Perlas para urgenciólogos
465-7
35
6
Diciembre
2023
465
467
Download in PDF < Volver
El remdesivir para tratar la COVID-19: una revisión Cochrane
Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, Metzendorf MI, Stegemann M, Benstoem C, Fichtner F
Department of Intensive Care Medicine, Medical Faculty, RWTH Aachen University, Aachen, Alemania. Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, Leipzig, Alemania. Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Alemania. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Alemania. Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Alemania.
Síguenos en:
